DDInter629 DDInter1435
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Bepridil
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Eliglustat may lead to a major life threatening interaction when taken with Bepridil
Eliglustat may lead to a major life threatening interaction when taken with Dacomitinib